Inhibition of TGFβ-induced Fibroblast to Myofibroblast Transition by Conditioned Medium from Human Rhinovirus-infected Airway Epithelial Cells is Mediated by Prostaglandin E$_2$

Diana Pham  
University of Calgary

Cora Kooi  
University of Calgary

David Proud  
University of Calgary

Richard Leigh  (✉ rleigh@ucalgary.ca)  
University of Calgary

---

Research Article

**Keywords:** Human rhinovirus, epithelial cells, fibroblasts, myofibroblasts, prostanoids.

**Posted Date:** January 21st, 2022

**DOI:** https://doi.org/10.21203/rs.3.rs-1273263/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
[Read Full License](https://creativecommons.org/licenses/by/4.0/)
Abstract

**Background:** Airway remodeling, including increased deposition of extracellular matrix proteins, is a hallmark of asthma. Myofibroblasts, derived via fibroblast to myofibroblast transition (FMT), play an important role in this increased deposition of matrix proteins. Expression of transforming growth factor b1 (TGFb1) is increased in asthmatic airways and is known to induce FMT, as assessed by increased expression of a-smooth muscle actin (a-SMA). Because human rhinovirus (HRV) infections of airway epithelial cells have been linked to the generation of mediators involved in airway remodeling, we tested the hypothesis that conditioned medium from HRV-infected human airway epithelial cells from healthy normal subjects would enhance FMT, either alone or in combination with TGFb1.

**Methods:** FMT was assessed by measuring a-SMA expression in human airway fibroblasts, both by western blotting and by immunohistochemistry. Statistical analysis was performed using ANOVA and Holm-Sidak or Bonferonni post hoc tests.

**Results:** Our data showed that conditioned medium from HRV infected epithelial cells significantly inhibited TGFb1-induced expression of a-SMA in fibroblasts when compared to conditioned medium from uninfected epithelial cells. Treatment of epithelial cells with the nonselective cyclooxygenase inhibitor, diclofenac, during HRV infection significantly reversed the inhibitory effects of conditioned medium on TGFb1-induced expression of a-SMA. This led us to hypothesize that HRV-infected epithelial cells release PGE$_2$ that acts on EP receptors to suppress TGFb1-induced expression of a-SMA in fibroblasts. We confirmed that HRV-infection of airway epithelial cells upregulated PGE$_2$ release, and that exposure of fibroblasts to PGE$_2$ significantly inhibited TGFb1-induced expression of a-SMA in fibroblasts. Finally, studies using selective agonists and antagonists demonstrated that PGE$_2$ inhibited TGFb1-induced expression of a-SMA in fibroblasts via effects at the EP$_2$ receptor.

**Conclusions:** Thus, using cells derived from healthy normal subjects we demonstrate that HRV infection of airway epithelial cells induces release of PGE$_2$ that acts on EP$_2$ receptors on fibroblasts to suppress TGFb1-induced FMT. Additional studies are needed to determine if a different pattern of response is seen using cells from asthmatic subjects to determine if the inhibitory role of PGE$_2$ on FMT in normal cells helps prevent airway remodeling in normal subjects.

Introduction

The term airway remodeling is used to describe the collection of structural changes in the airways of patients with asthma. These changes, which begin to manifest in early childhood, include increased mass of airway smooth muscle, goblet cells hypertrophy and associated mucus hypersecretion, angiogenesis, and increased matrix protein deposition, particularly in the lamina reticularis[1, 2]. Increased matrix protein deposition is associated with increased numbers of fibroblasts and myofibroblasts near the laminar reticularis[1, 3]. Both fibroblasts and myofibroblasts can secrete multiple extracellular matrix proteins. Myofibroblasts, display characteristics of both fibroblasts and smooth
muscle cells[4], making them difficult to identify, except via ultrastructural analysis using electron microscopy, which is considered the "gold standard" for identifying these cells [5, 6]. Myofibroblasts, which, unlike fibroblasts, express a-smooth muscle actin (a-SMA)[7] are thought to be more metabolically active than fibroblasts based on greater expression and enhanced production of matrix proteins, including collagens I, III and V, as well as fibronectin and tenascin[8, 9]. As such, they are thought to be important contributors to remodeling in asthma[10].

The origin of myofibroblasts is a topic of debate with suggestions that they can derive from fibrocytes, via epithelial mesenchymal transition, or from smooth muscle to myofibroblast transition[11-13]. Considerable evidence, however, also supports that fibroblast to myofibroblast transition (FMT) is a source of myofibroblasts in airway tissues[8]. This process, which includes increased expression of a-SMA, activation of focal adhesion kinases, formation of stress fibers ultimately leads to myofibroblasts that exhibit decreased motility and proliferative abilities but increased contractile properties and enhanced secretion of matrix proteins[6, 8]. Various stages of FMT can be regulated by a number of mechanical factors, as well as by cytokines, and growth factors, with transforming growth factor-b (TGFb) being the most studied[13, 14]. It is established that TGFb, levels of which are increased in asthma [14], can induce FMT in fibroblasts from both healthy and asthmatic subjects with asthmatic cells showing an increased potential to transition[8, 15].

Recent studies support the potential for human rhinovirus (HRV) infections to contribute to aspects of airway remodeling by changing the biology of infected airway epithelial cells, one of the initiating cells involved in remodeling[2]. It has been shown that HRV-infected airway epithelial cells release increased levels of several chemokines, growth factors and proteases linked to angiogenesis or to matrix remodeling[16-19]. In addition, there is evidence that HRV infection of airway epithelial cells can contribute to epithelial mesenchymal transition[20]. In the current study, therefore, we examined the potential of HRV infection of human airway epithelial cells to cause the release of products that may regulate FMT either alone, or in combination with TGFb. Surprisingly, we demonstrate that conditioned medium from HRV-infected airway epithelial cells significantly inhibit TGFb-induced FMT via a PGE₂-mediated mechanism.

Methods

Cell culture

All tissue culture products were purchased from ThermoFisher Scientific (Waltham, MA) except where indicated. Primary human bronchial epithelial (HBE) and fibroblast (HBF) cells were isolated from non-transplanted normal human lungs obtained through a tissue retrieval service (International Institute for the Advancement of Medicine, Edison, NJ) with approval from the Conjoint Health Research Ethics Board of the University of Calgary and the Internal Ethics Board of the International Institute for the Advancement of Medicine. Airways up to around the 4th generation were dissected from the lung parenchyma. For fibroblast cell isolation, a section of mainstem bronchus was cut up into 1-2 mm pieces.
and placed in 24-well plates containing dMEM, 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). After approximately two weeks, fibroblast cells that migrated out of the tissue plugs were expanded, enumerated and frozen in aliquots at -80°C. For epithelial cell isolation, the remaining airway pieces were submerged in sterile Ham’s F12 medium containing 1 µl/ml gentamicin and 1 mg/ml pronase (MilliporeSigma, Burlington, MA) for approximately 36 hours at 4°C. The airway pieces were then submerged in F12 containing 10% heat inactivated FBS and epithelial cells were removed from the surface by jetting pre-warmed medium repeatedly over the exposed surface using a 5 ml syringe. Epithelial cells were routinely grown in 6-well plates in complete PromoCell (Heidelberg, Germany) epithelial cell growth medium at 37°C for 14 days. Fibroblasts were seeded in either six-well plates or chamber slides at a seeding density of 1.5 X 10^6 or 0.5 X 10^5 cells, respectively. HBF cells were grown in dMEM supplemented with 10% fetal bovine serum (FBS). For consistency, conditioned medium from 6 different HBE donors were pooled and aliquoted to use in experiments. Values of n correspond to the number of different individual fibroblast donors used in each experiment. Information on HBE and HBF donors used is provided (Supplemental Table 1).

**HRV purification**

HRV major group strain 16 (HRV-16) was propagated in WI-38 fetal lung fibroblasts cells (American Type Culture Collection, Rockville, MD) and purified by sucrose density centrifugation as previously described [21].

**Treatment of human bronchial epithelial cells**

After 14 days of growth, HBE cells at approximately 70% confluency were pre-treated for 24 h with PromoCell epithelial growth medium with the hydrocortisone removed to minimize the potential effects of steroids. Four hours prior to treatment, HBE cells were pre-treated with PromoCell basal epithelial medium. HBE cells were infected with HRV-16 at a multiplicity of infection of ~1 in PromoCell basal medium or treated with basal medium alone. In some experiments, HBE cells were pretreated for 30 min with diclofenac (10^-6 M). The 24h conditioned medium was collected and centrifuged at 1200 rpm at 4°C for 8 minutes. The supernatant layer was transferred to another tube and stored in aliquots at -80°C for future supernatant analysis or co-culture with fibroblasts.

**Enzyme linked immunosorbent assays (ELISAs)**

Levels of CXCL10, CXCL8 and PGE_2 released from the HBE cells in response to viral infection were measured by ELISA. The assay for PGE_2 was purchased from Cayman Chemical (Ann Arbor, MI). CXCL10 was assayed using antibodies from Peprotech (East Windsor, NJ). Levels of CXCL8 were measured using a previously described ELISA developed in our laboratory [22].
Treatment of human bronchial fibroblast cells

HBF cells were pre-treated with dMEM, PSF and no serum for 2 hours prior to exposure. Fibroblasts were then treated with a 1:1 (vol/vol) mixture of dMEM containing 0.1% BSA and conditioned medium from either HBE infected with HRV or uninfected control HBE. TGFβ1 was also added with certain treatments to act as a positive control or as a co-stimulus. In some experiments HBF cells were pre-treated with individual antagonists for the EP₁ receptor (SC51322), EP₂ receptor (TG4-155), EP₃ receptor (L798106), EP₃ antagonist (L798106), or the EP₄ receptor (L161982). Cells were preincubated with selective EP receptor antagonists (100 mM) for 30 min. For these experiments, each antagonist was also present throughout the 48h incubation. In other experiments, HBF cells were treated with the EP₁-4 agonists, ONO-D1-004, ONO-AE1-259-01, ONO-AE-248, ONO-AE1-329, respectively (generously provided by Dr. Mark Giembycz, University of Calgary). After 48 hours, -SMA expression levels were assessed by immunochemistry and/or western blotting. Cell viability was also assessed using a Thiazolyl Blue Tetrazolium Bromide (MTT) assay (MilliporeSigma).

Immunohistochemical assessment of α-SMA expression in fibroblasts

After 48 hours of treatment, chamber slides containing HBF cells were fixed in a 25% acetone/75% ethanol mixture for 10 minutes at -20°C. The slides were treated with 0.03% H₂O₂ in phosphate buffered saline (PBS) for 3 minutes. Following three PBS washes (pH 7.2-7.6), the cells were blocked with a 2% normal goat serum application for 30 minutes. α-SMA primary antibody (catalog # ab5694; Abcam, Cambridge, UK) diluted 1:125 in antibody diluent (DAKO, Santa Clara, CA) was applied for 90 minutes at room temperature. Following thorough PBS washing, a 1:200 dilution of secondary antibody in antibody diluent was applied for 45 minutes at room temperature. After washing with PBS, the slides were incubated with peroxidase labelled avidin biotin complex for 30 minutes at room temperature. Washes with PBS and rinses with distilled H₂O were then performed prior to a 5 minute application of 3,3′-Diaminobenzidine (DAB) chromogen solution. The slides were washed five times with dH₂O and then counterstained with Gills II hematoxylin for 20 seconds followed by warm water for 2 minutes. A series of dehydration steps was then performed using 95% ethanol and 2 changes of 100% isopropanol for 2 minutes at each change, followed by 2 changes in xylenes for 2 minutes before being mounted in permount (Thermofisher) for cover slip attachment. Chamber slides were left to dry for at least 24 hours before microscopic analysis.

Quantification of α-SMA positive cells by immunohistochemistry

A cell was considered α-SMA positive if they presented with a Hematoxylin-stained nucleus with brown-stained striations (α-SMA). TGFβ1 alone in media was used as a positive control on fibroblasts as it is well-established to induce α-SMA expression [15]. To determine the average amount of α-SMA positive cells per condition, α-SMA positive cells in the field of vision at 100X magnification at each of the four corners and the center of the slide were counted and summed together. The total number α-SMA positive
cells counted were then divided by 5 as there were a total of five fields of vision thus, representing the 
average number of α-SMA positive cells on the slide.

**Whole-cell lysates**

Post treatment, supernatants were aspirated, cells were washed with HBSS and fibroblasts were lysed in 
icy-cold lysis cocktail buffer made of 0.81% Triton X-100 in 1 X MES buffered saline pH 7.4 containing 2 
mM sodium orthovanadate, 20 mM sodium pyrophosphate, 50 mM sodium fluoride, 1X complete protease 
inhibitor (Roche, Basel, Switzerland) and 1 mM of phenylmethylsulfonyl fluoride (PMSF). To further 
ensure complete cell lysis, the cells in lysis buffer were placed at -80°C to undergo a freeze-thaw cycle, 
scraped and sonicated using a Branson 2510 Sonicator for 30 seconds. After sonication, the lysates were 
centrifuged at 10,000 x g for 5 min and the lysate supernatants were transferred to clean tubes. Lysates 
were analyzed for protein content using a DC Protein Assay (BioRad Laboratories, Mississauga, ON, 
Canada) as recommended by the manufacturer.

**Western blots**

Equivalent amounts of whole cell lysate were separated by 12% Sodium Dodecyl Sulfate-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE), and then transferred to a 0.45 μm nitrocellulose membrane. Membranes 
were blocked with 3% bovine serum albumin (BSA) in 0.05% Tween 20 tris-buffered saline (TTBS) for 1 h. 
The blots were washed three times in 0.05% TTBS for at least 5 min each time, followed by transfer into 
roller tubes containing α-SMA primary antibody in 3% BSA in 0.05% TTBS at a 1:2000 dilution, and 
incubated overnight at 4°C on a roller mixer. Following three 15 min washes, the blots were incubated 
with α-rabbit Ig-horseradish peroxidase (HRP) secondary antibody at a 1:10000 dilution in 0.1% TTBS for 
1 hour followed by three washes with 0.05% TTBS for 15 minutes. α-SMA protein levels were visualized 
using a digital imager (Bio-Rad, Hercules, CA) after a 1 min exposure to enhanced chemiluminescence 
(ECL) reagent for visualization of HRP activity. Membranes were then stripped and re-probed using 
antibody (AbD Serotec, Raleigh NC) to the housekeeping protein, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH).

**Densitometry analysis**

Densitometry analysis was performed using ImageJ software (version 1.41, National Institute of Health, 
Bethesda, MD). The fold change in expression of the protein of interest was determined by normalizing 
the raw pixel count of the protein of interest to the raw pixel count of the housekeeping protein, GAPDH. 
This was then compared to the normalized value for medium control. Data are expressed as fold change 
over medium control unless specified otherwise.

**EP₁₋₄ receptor expression in HBF cells**
To examine mRNA expression of PGE2 receptors in HBF, total cellular RNA was purified from cells using a Nucleospin isolation kit (Macherey-Nagal, Duren, Germany) and converted to cDNA using EasyScript™ reverse transcriptase (Applied Biological Materials, Inc., Richmond, BC, Canada) as recommended by the manufacturers. EP₁-⁴ receptors (PTGER1-PTGER4) were amplified and quantified using the primer sequences specific to each receptor (Supplemental Table 2). Relative quantification of each EP receptor gene expression was achieved by comparing to a 7-point standard curve generated using cDNA from myometrial cells, which highly express each receptor. GAPDH was used to ensure equal cDNA input.

**Statistical analysis**

All statistics were performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA). All data were expressed as mean ± standard error of the mean. The Kolmogorov-Sminov normality test determined the parametric or non-parametric status of the data sets. Parametric data were analyzed by one-way ANOVA with appropriate post hoc test. Data sets comparing two conditions were analyzed by using a paired or unpaired student t-test, as appropriate. For all statistical tests, a two-tailed p-value less than 0.05 was considered statistically significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

**Results**

We used western blotting and immunohistochemistry to evaluate the effects of conditioned medium from HRV-infected and uninfected (control) HBE on expression of α-SMA in fibroblasts, both alone, and in the presence of TGFβ1. Compared to conditioned medium from control HBE, conditioned medium from infected HBE caused a consistent, but not statistically significant, reduction in α-SMA expression when used alone. We confirmed prior data that TGFβ1 enhances fibroblast expression of α-SMA in a dose-dependent manner (Supplemental Figure 1). When conditioned medium from infected and non-infected HBE were used in conjunction with TGFβ1, conditioned medium from HRV-infected HBE significantly decreased expression of α-SMA when compared with control conditioned medium (Figure 1 A, B). This reduction was not due to cell death (Supplemental Figure 2). To further validate these observations, we performed a limited number of experiments (n=3) using immunohistochemistry for α-SMA and observed a similar pattern of α-SMA expression with the various treatments (Figure 1 C, D).

Prostaglandins are known to have multiple actions in the asthmatic airways[23]. To evaluate if prostanoids may play a role in the effects of conditioned medium from HRV-infected epithelial cells, we performed western blotting studies using the non-selective cyclooxygenase inhibitor, diclofenac. The data demonstrate that exposure of HBE to diclofenac during HRV-infection significantly reversed the inhibitory effect of conditioned medium on TGFβ-induced α-SMA expression in fibroblasts, although inhibition was not complete (Figure 2 A, B).

Given that PGE₂ has previously been shown to downregulate TGFβ1-induced α-SMA expression[24], we hypothesized that HRV-infected HBE release increased levels of PGE₂ that contribute to the inhibitory
effects of HRV-infected conditioned medium on TGFβ1-induced α-SMA expression. In support of this hypothesis, we observed that, while levels of PGE2 were undetectable in conditioned medium from non-infected epithelial cells, HRV-16 treatment of HBE cells resulted in a significant increase in PGE2 supernatant levels, with a mean value of 73.7 pg/ml. As expected, HRV-16 infected HBE no longer produced PGE2 in the presence of diclofenac (Figure 3).

We initially examined the effects of varying concentrations of PGE2 on basal expression of α-SMA in HBF cells. Although an inhibitory trend was observed, this did not achieve significance (Supplemental Figure 3). In the presence of 3 ng/ml of TGFβ1, however, increasing concentrations of PGE2 significantly decreased TGFβ1-induced α-SMA protein levels in fibroblasts (Figure 4).

PGE2 binds specifically to EP1-4 receptors, which are coupled to various signaling cascades, depending on receptor subtype. As an initial approach to examine potential receptor involvement, levels of mRNA for each receptor were examined by RT-PCR. The EP2 receptor was the predominant receptor expressed in HBF cells, followed by the EP4 receptor. Trace amounts of EP3 receptor expression were also detected (Supplemental Figure 4).

Selective EP receptor antagonists and agonists were used to further investigate the receptor-mediated pathway by which PGE2 suppresses TGFβ1-induced α-SMA. When fibroblasts were exposed to TGFβ1, in the presence or absence of PGE2, TGFβ1 alone increased α-SMA expression as expected. This was suppressed when PGE2 was added. In the presence of selective antagonists for each EP receptor subtype, only the EP2 receptor antagonist reversed PGE2-mediated reduction in TGFβ1-induced α-SMA expression (Figure 5). To further support the premise that PGE2 selectively binds to the EP2 receptor to mediate inhibition of TGFβ1 induced α-SMA expression, we examined the effects of selective agonists to each EP receptor subtype. Consistent with the data using antagonists, only the EP2 receptor agonist was able to suppress α-SMA expression in the presence of TGFβ1 (Figure 6).

**Discussion**

Given that earlier studies have shown that HRV-infection of human airway epithelial cells releases products that are known to contribute to airway remodeling [16-19], and that HRV-infections synergizes with TGFβ1 in triggering epithelial to mesenchymal transition [20], we initially hypothesized that conditioned medium from HRV-infected epithelial cells would enhance TGFβ1-induced FMT, as monitored by increased α-SMA expression. Our data consistently demonstrated, however, that medium from epithelial cells infected with HRV significantly inhibited the ability of TGFβ1 to induce α-SMA expression in airway fibroblasts, using both western blotting and immunohistochemistry for α-SMA.

Studies using the non-selective cyclooxygenase inhibitor, diclofenac, demonstrated that this drug significantly, but not completely, reversed the ability of conditioned medium from HRV-infected HBE to inhibit TGFβ1 to induce α-SMA expression in airway fibroblasts. This implied that, while other mediators
likely contribute to the inhibitory response seen, one or more prostaglandins play a significant role in inhibiting the ability of TGFβ1 to induce α-SMA expression in airway fibroblasts. It has previously been reported that HTV-infection of HBE can induce the generation of several prostaglandins, including PGE₂[25]. Because PGE₂ has previously been reported to inhibit TGFβ-induced α-SMA expression [24, 26], we tested the hypothesis that HRV infection induced production of from HBE and that this contributed to inhibition of TGFβ1-induced α-SMA expression in human airway fibroblasts. Our data clearly demonstrated that HRV infection of HBE induced release of PGE₂ at levels similar to those reported previously [25]. We also confirmed that PGE₂ inhibited TGFβ1-induced α-SMA expression in a concentration dependent manner. Although mRNA analysis showed that fibroblasts significantly expressed mRNA for both EP₂ and EP₄ receptors for PGE₂, data using both selective antagonists and agonists demonstrated that effects of PGE₂ were mediated entirely by interactions at the EP₂ receptor, a G-protein coupled receptor with a Gsa subunit that activated adenylyl cyclase to increase intracellular levels of cAMP[27].

It is apparent that the interaction of HRV-infected airway epithelial cells with airway fibroblasts is complex. Although our current data show that supernatants from infected epithelial cells can reduce FMT, HRV-infected cells also release chemokines that are chemotactic for fibroblasts and could contribute to increased fibroblast numbers in the region of the lamina reticularis [17]. Such fibroblasts also secrete matrix proteins that could lead to enhanced matrix protein deposition. Moreover, infected epithelial cells secrete a number of growth factors that can stimulate matrix protein deposition from fibroblasts and myofibroblasts[16].

A limitation of our study is that we used only epithelial cells and fibroblasts from healthy normal controls and, as such, our data may not fully represent data that may be obtained with cells derived from asthmatic airways. It is known that airway epithelial cells phenotype is altered in both children and adults with asthma [28, 29]. Moreover, several phenotypic changes in epithelial cells from asthmatic subjects, including increased expression of cytokeratin 5, altered production of cytokines and chemokines, and enhanced production of several growth factors linked to airway remodeling are maintained in culture[28, 30-33]. Thus, given that airway remodeling occurs in patients with asthma but not in healthy normal subjects, it would seem likely that epithelial cells from asthmatic subjects may exert properties that would be more supportive of aspects of remodeling. In support of this concept, it has been reported that co-culture of epithelial cells from asthmatic subjects with fibroblasts in the presence of TGFβ enhances expression compared to cells from normal subjects [26]. Interestingly, it has been reported that, while expression of TGFβ is increased upon co-culture of fibroblasts with asthmatic epithelial cells, expression of prostaglandin E₂ synthase is downregulated compared to co-cultures with normal epithelial cells [33]. Thus, one may speculate that enhanced PGE₂ expression in normal cells, along with reduced expression may help to prevent airway remodeling in normal subjects. Further studies will be required to address this. Finally, it must be noted that we are unaware of any studies thus far in which the interaction of asthmatic airway epithelial cells with fibroblasts also derived from asthmatic patients have been examined. It is
feasible that this such studies may further exaggerate differences between normal and asthmatic cell models.

In summary, our data demonstrate that HRV-induced production of PGE$_2$ from airway epithelial cells derived from normal subjects inhibits TGFβ-induced FMT. We speculate that this may contribute to preventing airway remodeling in normal subjects.

**Declarations**

**Ethics Approval**: Ethical approval to obtain cells from normal human lungs was obtained from both the Conjoint Health Research Ethics Board of the University of Calgary and the Internal Ethics Board of the International Institute for the Advancement of Medicine (Edison, NJ), the tissue retrieval service used to obtain lungs not used for transplant. Informed consent was obtained from next of kin of each donor.

**Consent for Publication**: Not applicable.

**Availability of Data**: The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Competing Interests**: The authors declare that they have no competing interests.

**Funding**: This work was supported by the Canadian Institutes of Health Research (Project grant PJT-159635). DMP was supported by scholarships from the Lung Association of Alberta and NWT, and the Goran-Enhorning Scholarship from Asthma Canada-Allergen NCE. DP holds a Tier 1 Canada Research Chair in Inflammatory Lung Diseases. RL holds the GlaxoSmithKline-CIHR Professorship in Inflammatory Lung Diseases.

**Authors Contributions**: DMP, DP and RL conceived and planned the experimental design. DMP performed experiments and analyzed data. CK derived and propagated the fibroblasts used in this study, provided technical support for all aspects of the study, and assisted in generating the data for Figure 1. All authors contributed to the writing and editing of the manuscript and all authors approved the final manuscript.

**Acknowledgements**: The authors gratefully acknowledge assistance from Shahina Wiehler in deriving epithelial cells and virus preparations.

**References**

1. Al-Muhsen S, Johnson JR, Hamid Q: Remodeling in asthma. J Allergy Clin Immunol2011, 128:451-462.

2. Hough KP, Curtiss ML, Blain TJ, Liu R-M, Trevor J, Deshane JS, Thannickal VJ: Airway remodeling in asthma. Front Med2020, 7:191.
3. Ingram JL, Huggins MJ, Church TD, Li Y, Francisco DC, Degan S, Firszt R, Beaver DM, Lugogo NL, Wang Y, et al: Airway fibroblasts in asthma manifest and invasive phenotype. Am J Respir Crit Care Med2011, 183:1625-1632.

4. Powell DW, Mifflin RC, Velentich JD, Crowe SE, Saada JI, West JB: Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol1999, 277:C1-C9.

5. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, De Wever O, Mareel M, Gabbiani G: Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol2012, 180:1340-1355.

6. Eyden B: The myofibroblast: phenotypic characterization as a prerequisite to understanding its function in translational medicine. J Cell Mol Med2008, 12:22-37.

7. Singh SR, Hall IP: Airway myofibroblasts and their relationship with airway myocytes and fibroblasts. Proc Am Thorac Soc2008, 5:127-132.

8. Michalik M, Wójcik K, Paw M, Wnuk D, Koczurkiewicz P, Sanak M, Pekala E, Madeja Z: Fibroblast-to-myofibroblast transition in bronchial asthma. Cell Mol Life Sci2018, 75:3943-3961.

9. Weitoft M, Andersson C, Andersson-Sjöland A, Tufvesson E, Bjermer L, Erjefalt J, Westergren-Thorsson G: Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions. Respir Res2014, 15:67.

10. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, Ludwig M, Martin J, G., Hamid Q: Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol2005, 116:544-549.

11. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol2003, 171:380-389.

12. McAnulty RJ: Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol2007, 39:666-671.

13. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ: Diverse origins of myofibroblasts—implications for kidney fibrosis. Nat Rev Nephrol2015, 11:233-244.

14. Redington AE, Madden J, Frew AJ, Djukanovic R, Roche W, Holgate ST, Howarth PH: Transforming growth factor-β1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med1997, 156:642-647.

15. Michalik M, Pierzchalska M, Legutko A, Ura M, Ostaszewska A, Soja J, Sanak M: Asthmatic bronchial fibroblasts demonstrate enhanced potential to differentiate into myofibroblasts in culture. Med Sci Monit2009, 15:BR194-201.

16. Leigh R, Oyelusi W, Wiehler S, Koetzler R, Zaheer RS, Newton R, Proud D: Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling. J Allergy Clin Immunol2008, 121:1238-1245.

17. Shelfoon C, Shariff S, Traves SL, Kooi C, Leigh R, Proud D: Chemokine release from human rhinovirus-infected airway epithelial cells promotes fibroblast migration. J Allergy Clin Immunol2016, 138:110-122.
18. Zhu L, Lee PK, Lee W-M, Zhao Y, Yu D, Chen Y: Rhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway. Am J Respir Cell Mol Biol 2009, 40:610-619.
19. Tacon CE, Wiehler S, Holden NS, Newton R, Proud D, Leigh R: Human rhinovirus infection of airway epithelial cells upregulates MMP-9 production via NF-κB. Am J Respir Cell Mol Biol 2010, 43:201-209.
20. Minor DM, Proud D: Role of human rhinovirus in triggering human airway epithelial-mesenchymal transition. Respir Res 2017, 18:110.
21. Sanders SP, Siekierski ES, Porter JD, Richards SM, Proud D: Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J Virol 1998, 72:934-942.
22. Subauste MC, Jacoby DB, Richards SM, Proud D: Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 1995, 96:549-557.
23. Claar D, Hartert TV, Peebles RS: The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med 2015, 9:55-72.
24. Penke LRK, Huang SK, White ES, Peters-Golden M: Prostaglandin E2 inhibits β2-smooth muscle actin transcription during myofibroblast differentiation via distinct mechanisms of modulation of serum response factor and myocardin-related transcription factor-α. J Biol Chem 2014, 289:17151-17162.
25. Van Ly D, Faiz A, Jenkins C, Crossett B, Black JL, McPartland B, Burgess JK, Oliver BGG: Characterising the mechanism of airway smooth muscle β2 adrenoreceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS One 2013, 8:e56058.
26. Reeves SR, Kolstad T, Lien T-Y, Herrington-Shaner S, Debley JS: Fibroblast-myofibroblast transition is differentially regulated by bronchial epithelial cells from asthmatic children. Respir Res 2015, 16:21.
27. Narumiya S: Prostanoid receptors. Structure, function, and distribution. Ann N Y Acad Sci 1994, 744:126-138.
28. Carsin A, Mazenq J, Ilstad A, Dubus J-C, Chanez P, Gras D: Bronchial epithelium in children: a key player in asthma. Eur Respir Rev 2016, 25:158-169.
29. Loxham M, Davies DE, Blume C: Epithelial function and dysfunction in asthma. Clin Exp Allergy 2014, 44:1299-1313.
30. Hackett T-L, Singhera GK, Shaheen F, Hayden P, Jackson GR, Hegele RG, Van Eeden S, Bai TR, Dorscheid DR, Knight DA: Intrinsic phenotypic differences of asthmatic epithelium and its inflammatory responses to respiratory syncytial virus and air pollution. Am J Respir Cell Mol Biol 2011, 45:1090-1100.
31. Kicic A, Sutanto EN, Stevens PT, Knight DA, Stick SM: Intrinsic biochemical and functional differences in bronchial epithelial cells of children with asthma. Am J Respir Crit Care Med 2006, 174:1110-1118.
32. Lopez-Guisa JM, Powers C, File D, Cochrane E, Jiminez N, Debley JS: Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol 2012,
33. Reeves SR, Kolstad T, Lien Y-U, Elliott M, Ziegler SF, Wight TN, Debley JS: Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components. J Allergy Clin Immunol 2014, 134:663-670.

**Figures**

**Figure 1**

**HRV-16 conditioned supernatant modulated TGFβ1-induced α-SMA expression in human bronchial fibroblasts.**

A. Representative western blot analysis of α-SMA in a HBF donor stimulated with medium alone, 1 ng/ml TGFβ1 alone, conditioned medium from non-infected epithelial cells (HBE-Con), conditioned medium from HRV-16 infected epithelial cells (HBE-HRV), HBE-Con in combination with 1 ng/ml TGFβ1 and HBE-HRV in combination with 1ng/ml of TGFβ1. B. Densitometric analysis of α-SMA protein expression normalized over GAPDH protein expression in from 8 different fibroblast donors. Data were analyzed by
one-way ANOVA with post-hoc test Bonferroni’s multiple comparisons test. Data are expressed as mean ± SEM (ns = not significant). **C.** Representative immunohistochemical analysis at 100X magnification of α-SMA positive cells after 48 h of stimulations. Brown stains represent the location and presence of α-SMA. Data were expressed as mean± SEM and are representative of n=3. **D.** Densitometric analysis of immunohistochemical data from the 3 donors.

**Figure 2**

**Diclofenac reverses HBE-HRV mediated suppression of TGFb stimulated α-SMA expression in HBFs.**

**A.** Representative western blot analysis of α-SMA in HBFs exposed to TGFβ1 combined with conditioned medium from HRV-infected HRV stimulated in the presence or absence of diclofenac. **B.** Mean densitometric analysis of α-SMA normalized over GAPDH expression in HBFs from all experiments. Data are expressed as mean ± SEM (n=8). Parametric data were statistically analyzed using a one way-ANOVA with appropriate post-hoc testing using the Holm-Sidak multiple comparison test.
Figure 3

ELISA analysis of prostaglandin E\textsubscript{2} level in supernatants from human bronchial epithelial cells after 24 h treatments.

Prostaglandin E\textsubscript{2} levels detected in conditioned medium from control cells (HBE-Con) or HBE infected with HRV alone (HBE-HRV) or in the presence of diclofenac. Data were analyzed by one-way ANOVA followed by Bonferroni’s multiple comparisons test. Data are expressed as mean ± SEM (n=6). Values under the minimum detection limit (7.8 pg/ml) were arbitrarily assigned a value of 3.9 pg/ml.
Figure 4

PGE\textsubscript{2} significantly inhibits TGF\textbeta{1}-induced \textalpha-SMA expression in HBFs.

A. Representative western blot analysis of \textalpha-SMA and GAPDH in HBFs after exposure to TGF\textbeta{1} in the presence or absence of varying concentrations of PGE\textsubscript{2}. B. Densitometric analysis of \textalpha-SMA normalized over GAPDH expression in all experiments (n=5). Data are expressed as mean ± SEM and were analyzed using one way-ANOVA with post-hoc testing comparing each value to the control using Dunnett’s multiple comparison test.
**Figure 5**

**Effects of selective EP receptor antagonists on the inhibition by PGE\(_2\) of TGFβ1-induced α-SMA expression.**

A. Representative western blot of α-SMA and GAPDH in HBFs exposed to: 1) medium alone, 2) TGFβ1 alone, 3) TGFβ1 and PGE\(_2\), 4) TGFβ1 and PGE\(_2\) in the presence of EP\(_1\) antagonist (SC51322), 5) TGFβ1 and PGE\(_2\) in the presence of EP\(_2\) antagonist (TG4-155), 6) TGFβ1 and PGE\(_2\) in the presence of EP\(_3\) antagonist (L798106), 7) TGFβ1 and PGE\(_2\) in the presence of EP\(_4\) antagonist (L161982). Followed by EP\(_4\) antagonist, TGFβ1 and PGE\(_2\). All EP antagonists were used at a concentration of 100 nM. B. Densitometric analysis of α-SMA normalized over GAPDH expression for all experiments (n=8). Data were analyzed using one-way ANOVA and post-hoc test Bonferroni’s multiple comparisons test. Data are expressed as mean ± SEM.
Figure 6

**Effects of selective EP receptor agonists on TGFβ1-induced α-SMA expression.**

A. Representative western blot of α-SMA and GAPDH in HBFs exposed to: 1) medium alone, 2) TGFβ1 alone, 3) TGFβ1 and EP₁ agonist (ONO-D1-004), 4) TGFβ1 and EP₂ agonist (ONO-AE1-259-01), 5) TGFβ1 and EP₃ agonist (ONO-AE-248), and 6) TGFβ1 and EP₄ agonist (ONO-AE1-329). All EP agonists were used at a concentration of 1 μM. B. Densitometric analysis of α-SMA normalized over GAPDH expression for all experiments (n=7). Data were analyzed using one-way ANOVA and post-hoc test Bonferroni's multiple comparisons test. Data are expressed as mean ± SEM.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarydata.docx](#)